Status:
COMPLETED
Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Lymphoid Malignancies
Eligibility:
All Genders
16-60 years
Phase:
PHASE2
Brief Summary
Allogeneic stem cell transplantation is potential curative therapy for adult lymphoid malignancies. Based on our previous study, the condition with iv-busulfan (iv-BU) and cyclophosphamide (CTX) is fe...
Detailed Description
Patients with adult lymphoid malignancies received conditioning with Fludarabine + iv-BU. The GVHD was consisting of D+3 and D+4 CTX after stem cell transfusion. CSA will be added for all patients aft...
Eligibility Criteria
Inclusion
- adult acute lymphocytic leukemia in 1st or second remission; lymphoid malignancies in 1st or second remission
- age 16-60 years
- with inform consent
- no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage
- HLA matched related (6/6), unrelated donors (at least 8/10) or mismatched related donor (haplo)
Exclusion
- age less than 16 years or over 60 years
- liver function/renal function damage (over 2 X upper normal range)
- with mental disease
- other contraindication of all-HSCT
Key Trial Info
Start Date :
April 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2018
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01435447
Start Date
April 1 2011
End Date
October 1 2018
Last Update
November 2 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Blood and Marrow Transplantation Center, Rui Jin Hospital
Shanghai, Shanghai Municipality, China, 200025